Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.

Decker KF, Zheng D, He Y, Bowman T, Edwards JR, Jia L.

Nucleic Acids Res. 2012 Nov;40(21):10765-79. doi: 10.1093/nar/gks888. Epub 2012 Sep 27.

2.

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.

Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18.

3.

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Peacock SO, Fahrenholtz CD, Burnstein KL.

Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.

4.

Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.

Li S, Hu MG, Sun Y, Yoshioka N, Ibaragi S, Sheng J, Sun G, Kishimoto K, Hu GF.

Mol Cancer Res. 2013 Oct;11(10):1203-14. doi: 10.1158/1541-7786.MCR-13-0072. Epub 2013 Jul 12.

5.

Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.

Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A.

Prostate. 2013 Nov;73(15):1699-709. doi: 10.1002/pros.22711. Epub 2013 Jul 19.

PMID:
23868789
6.

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL 3rd, Ghosh PM.

Cancer Res. 2010 Jul 15;70(14):5994-6003. doi: 10.1158/0008-5472.CAN-09-4440. Epub 2010 Jun 29.

7.

TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.

Takayama K, Horie-Inoue K, Suzuki T, Urano T, Ikeda K, Fujimura T, Takahashi S, Homma Y, Ouchi Y, Inoue S.

Mol Endocrinol. 2012 May;26(5):748-61. doi: 10.1210/me.2011-1242. Epub 2012 Mar 28.

PMID:
22456197
8.

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.

Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, Tanner MJ, Shtutman M, Vacherot F, Terry S, de la Taille A, Buttyan R.

Mol Cancer. 2010 Apr 26;9:89. doi: 10.1186/1476-4598-9-89.

9.

Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.

Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT, Narayanan R.

Clin Cancer Res. 2013 Oct 15;19(20):5613-25. doi: 10.1158/1078-0432.CCR-13-1151. Epub 2013 Aug 30.

10.

Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.

Shiota M, Yokomizo A, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Fujimoto N, Seki N, Naito S.

Mol Endocrinol. 2010 Jan;24(1):114-27. doi: 10.1210/me.2009-0302. Epub 2009 Nov 2.

PMID:
19884383
11.

Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.

Krause WC, Shafi AA, Nakka M, Weigel NL.

Int J Biochem Cell Biol. 2014 Sep;54:49-59. doi: 10.1016/j.biocel.2014.06.013. Epub 2014 Jul 4.

12.

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.

Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ, Vander Griend DJ.

PLoS One. 2013;8(1):e53701. doi: 10.1371/journal.pone.0053701. Epub 2013 Jan 11.

13.

Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.

Savoy RM, Chen L, Siddiqui S, Melgoza FU, Durbin-Johnson B, Drake C, Jathal MK, Bose S, Steele TM, Mooso BA, D'Abronzo LS, Fry WH, Carraway KL 3rd, Mudryj M, Ghosh PM.

Endocr Relat Cancer. 2015 Jun;22(3):369-86. doi: 10.1530/ERC-15-0021. Epub 2015 Mar 10.

14.

The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.

Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, Neal DE.

Cancer Cell. 2013 Jan 14;23(1):35-47. doi: 10.1016/j.ccr.2012.11.010. Epub 2012 Dec 20.

15.

Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.

Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T, Naito S.

Oncogene. 2010 Jan 14;29(2):237-50. doi: 10.1038/onc.2009.322. Epub 2009 Oct 5.

PMID:
19802001
16.

Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.

Robinson JL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, Papoutsoglou N, Neal DE, Tilley WD, Carroll JS.

Oncogene. 2014 Dec 11;33(50):5666-74. doi: 10.1038/onc.2013.508. Epub 2013 Dec 2.

17.

Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.

Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M.

PLoS One. 2011;6(9):e25341. doi: 10.1371/journal.pone.0025341. Epub 2011 Sep 29.

18.

Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.

Yang M, Wang J, Wang L, Shen C, Su B, Qi M, Hu J, Gao W, Tan W, Han B.

Prostate. 2015 Sep;75(13):1363-75. doi: 10.1002/pros.23017. Epub 2015 May 27.

PMID:
26015225
19.

Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y, Naito S.

Endocr Relat Cancer. 2011 Jul 11;18(4):505-17. doi: 10.1530/ERC-11-0017. Print 2011 Aug.

20.

Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.

Sharifi N, Hurt EM, Thomas SB, Farrar WL.

Clin Cancer Res. 2008 Oct 1;14(19):6073-80. doi: 10.1158/1078-0432.CCR-08-0591.

Items per page

Supplemental Content

Write to the Help Desk